GT Biopharma (GTBP) Net Income towards Common Stockholders (2010 - 2026)

GT Biopharma (GTBP) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 334.15% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$37.0 million (down 217.36% YoY), while the FY2025 annual figure was -$34.4 million, down 161.73% from the prior year.
• Net Income towards Common Stockholders improved to -$3.4 million in Q1 2026 per GTBP's latest filing, from -$7.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $4.1 million in Q3 2025 and bottomed at -$220.0 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$26.5 million across 5 years, with a median of -$3.7 million in 2023.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 4922.0% — and 2025, when it soared 220.11%.
• GT Biopharma's Net Income towards Common Stockholders stood at -$114.7 million in 2022, then surged by 97.43% to -$2.9 million in 2023, then retreated by 28.05% to -$3.8 million in 2024, then plunged by 99.1% to -$7.5 million in 2025, then soared by 55.18% to -$3.4 million in 2026.
• Business Quant data shows GTBP's Net Income towards Common Stockholders at -$3.4 million in Q1 2026, -$7.5 million in Q4 2025, and $4.1 million in Q3 2025.